4D Molecular Therapeutics, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
4D Molecular Therapeutics, Inc. (FDMT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $260.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $260.92M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $218.35M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $15.45M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $30.15M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2026-06-30 | $260.92M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $218.35M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $15.45M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $30.15M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $114.70M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $83.45M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $69.95M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $23.83M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $304.78M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $209.56M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $20.49M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $12.78M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $24.77M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $29.43M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $97.47M 10-K · filed 2024-02-29 | $97.50M 10-K · filed 2023-03-15 |
| 2022-09-30 | $64.60M 10-Q · filed 2022-11-08 | |
| 2021-12-31 | $162.40M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |